S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
IBO · Impact BioMedical, Inc.
NYSE MKT LLC - BOATS Real Time Price • USD
$3.13
+0.09
(+2.96%)
● At close: October 21 at 4:00:00 PM EDT
$3.70
-0.32
(-7.96%)
Overnight:
11:38:41 PM EDT
DAY'S RANGE
$3.13
$3.13
$3.13
52-WEEK RANGE
$3.13
$2.43
$10.47
What's happening
- IBO is up 2.96% today, trading at $3.13. — Live quote
- Volume today (247) is well below its 3-month average of 11,000. (Finnhub fundamentals)
- Reports earnings on 2026-11-06, 15 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
IBO
-48.70%
vs S&P 500
-61.48%
1-YEAR RETURN
IBO
-56.14%
vs S&P 500
-70.70%
6-MONTH RETURN
IBO
-60.96%
3-MONTH RETURN
IBO
-41.34%
Valuation Measures & Ratios
Enterprise Value4$29.2M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)797.61
Price / Book74.61
EV4 / Revenue835.33
EV4 / EBITDA—
Profit Margin2254.29%
Operating Margin-14597.14%
Return on Equity (ROE8)19.45%
Return on Assets (ROA9)4.54%
Avg Volume (3M)11,000
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $429.0M | $886.2M | $100.0M | $99.4M | $383.8M |
| P/E | -22.82 | -45.75 | -7.79 | -8.11 | 339.93 |
| Price/Sales | 12258.46 | — | — | — | — |
| Price/Book | 39.85 | 77.30 | -8.47 | -9.61 | 99.87 |
| EV/Revenue | 12258.46 | — | — | — | — |
| EV/EBITDA | -108.70 | -208.22 | -32.28 | — | — |
| ROE | -174.64% | -168.96% | 108.70% | 118.51% | 29.38% |
| ROA | -112.28% | -113.37% | -70.50% | -64.30% | 5.63% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short30,169
Change from Prior Settlement-94.28%
% of Float—
Days to Cover (Short Ratio)1.98
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Net profit margin is 2254.3%. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-09; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -57.1% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is -56.1%. Finnhub market metrics ↗
- Trailing P/E is 35.4, a high price relative to reported earnings. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on IBO
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0K | $7.0K | $18.0K | $7.0K | — | — | — | — |
| Operating income | -$702.0K | -$2.3M | -$948.0K | -$1.2M | -$1.0M | -$1.1M | -$626.0K | -$771.0K |
| Net income | -$699.0K | -$2.3M | -$1.5M | -$14.3M | -$1.3M | $4.2M | -$889.0K | -$962.0K |
| EPS (diluted) | $-0.01 | $-0.02 | $-0.12 | $-1.18 | $-0.11 | $0.06 | $-0.09 | $-0.10 |
| EPS (basic) | $-0.01 | $-0.02 | $-0.12 | $-1.18 | $-0.11 | $0.37 | $-0.09 | $-0.10 |
| Operating margin | -$23.4K | -$32.7K | -$5.3K | -$16.5K | — | — | — | — |
| Net margin | -$23.3K | -$32.7K | -$8.2K | -$204.9K | — | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $16.7M | $17.1M | $17.4M | $18.2M | $19.1M | $20.1M | $20.3M | $46.7M |
| Total liabilities | $2.7M | $2.4M | $1.9M | $27.1M | $26.4M | $13.2M | $13.1M | $12.3M |
| Stockholders' equity | $10.8M | $11.5M | $12.3M | -$11.8M | -$10.3M | $3.8M | $4.3M | $31.3M |
| Total current assets | $320.0K | $377.0K | $411.0K | $917.0K | $1.5M | $2.2M | $2.4M | $3.2M |
| Total current liabilities | $2.0M | $1.7M | $1.2M | $23.8M | $23.2M | $10.0M | $9.8M | $1.1M |
| Cash & equivalents | — | $20.0K | $3.0K | $12.0K | $624.0K | $1.3M | $2.0M | $2.7M |
| Accounts receivable | — | — | $5.0K | $15.0K | — | $4.0K | — | — |
| Inventory | $62.0K | $63.0K | $63.0K | $485.0K | $486.0K | $489.0K | — | — |
| Property, plant & equipment | — | — | — | $13.0K | $14.0K | $16.0K | $17.0K | $282.0K |
| Goodwill | — | — | — | — | — | — | $25.1M | $25.1M |
| Intangible assets | $16.4M | $16.7M | $17.0M | $17.3M | $17.6M | $17.9M | $17.8M | $18.1M |
| Accounts payable | $467.0K | $374.0K | $347.0K | $576.0K | $554.0K | $615.0K | $314.0K | $1.0M |
| Accrued liabilities | $248.0K | $210.0K | $194.0K | $336.0K | $266.0K | $217.0K | $194.0K | $102.0K |
| Other current liabilities | $1.3M | $1.1M | $621.0K | — | — | — | $399.0K | — |
| Common stock & paid-in capital | $108.0K | $108.0K | $105.0K | $12.0K | $12.0K | $12.0K | $11.0K | $11.0K |
| Retained earnings | -$52.5M | -$51.8M | -$49.5M | -$54.8M | -$53.3M | -$38.9M | -$37.7M | -$10.6M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $470.0K | -$464.0K | $99.0K | -$613.0K | -$694.0K | -$682.0K | -$986.0K | -$1.0M |
| Investing cash flow | $2.0K | -$1.0K | $1.0K | $1.0K | $0 | $1.0K | $0 | $1.0K |
| Financing cash flow | — | $482.0K | -$109.0K | — | — | — | $317.0K | $3.7M |
| Depreciation & amortization | $284.0K | $285.0K | $286.0K | $288.0K | $288.0K | $283.0K | $279.0K | $281.0K |
| Share-based compensation | $0 | $1.4M | $8.0K | $1.0K | $2.0K | $2.0K | $19.0K | — |
| Deferred income taxes | — | — | -$2.6M | — | — | — | $33.0K | — |
| Change in accounts receivable | $0 | -$5.0K | -$10.0K | $15.0K | -$4.0K | — | $0 | -$128.0K |
| Change in inventory | -$1.0K | — | -$3.0K | -$1.0K | -$3.0K | — | — | — |
| Change in accounts payable | $93.0K | $27.0K | $607.0K | $22.0K | -$61.0K | -$98.0K | -$605.0K | $15.0K |
| Debt issued | — | — | — | — | — | — | $317.0K | -$60.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Revenue | $32.0K | — | — | $50.0K |
| Operating income | -$4.3M | -$28.8M | -$4.0M | -$3.4M |
| Net income | -$11.8M | -$24.7M | -$4.3M | -$7.3M |
| EPS (diluted) | $-0.38 | $-2.30 | $-0.07 | $-0.10 |
| EPS (basic) | $-0.38 | $-2.30 | $-0.07 | $-0.10 |
| Operating margin | -$13.4K | — | — | -$6.8K |
| Net margin | -$37.0K | — | — | -$14.5K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Sep '23 | Dec '22 |
|---|---|---|---|---|---|
| Total assets | $17.4M | $20.3M | $44.6M | — | $46.5M |
| Total liabilities | $1.9M | $13.1M | $16.4M | — | $13.8M |
| Stockholders' equity | $12.6M | $4.3M | $25.2M | — | $29.6M |
| Total current assets | $411.0K | $2.4M | $332.0K | — | $122.0K |
| Total current liabilities | $1.2M | $9.8M | $13.1M | — | $10.6M |
| Cash & equivalents | $3.0K | $2.0M | $1.0K | — | $2.0K |
| Accounts receivable | $5.0K | — | — | — | — |
| Inventory | $63.0K | — | — | — | — |
| Property, plant & equipment | — | $17.0K | $287.0K | — | $276.0K |
| Goodwill | — | — | $25.1M | $46.4M | $25.1M |
| Intangible assets | $17.0M | $17.8M | $18.9M | — | $20.0M |
| Accounts payable | $347.0K | $314.0K | $832.0K | — | $539.0K |
| Accrued liabilities | $194.0K | $194.0K | $230.0K | — | $63.0K |
| Other current liabilities | $621.0K | $399.0K | — | — | — |
| Common stock & paid-in capital | $105.0K | $11.0K | $10.0K | — | $70.0K |
| Retained earnings | -$49.5M | -$37.7M | -$13.0M | — | -$8.6M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Operating cash flow | -$1.9M | -$2.9M | -$2.9M | -$2.2M |
| Investing cash flow | $3.0K | $2.0K | -$15.0K | -$349.0K |
| Financing cash flow | -$109.0K | $4.8M | $2.9M | $2.5M |
| Depreciation & amortization | $1.1M | $1.1M | $1.1M | $1.1M |
| Share-based compensation | $13.0K | $19.0K | — | — |
| Deferred income taxes | -$2.6M | $33.0K | — | -$621.0K |
| Change in accounts receivable | $1.0K | -$128.0K | — | — |
| Change in inventory | -$7.0K | — | — | — |
| Change in accounts payable | $470.0K | -$436.0K | $293.0K | $424.0K |
| Debt issued | — | $1.1M | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding IBO as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 17 most recent filings · covers 2024-09-16 to 2026-09-24
Recent transactions
- Insiders have net sold 906 shares over the last 182 days, across 0 purchases and 3 sales.
- Most recent: DSS, INC. (10% owner) — Open market sale of 156 shares on 2026-09-24.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)906 sh(3 txns)
Net Shares-906
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| DSS, INC. | 10% owner | Open market sale | 2026-09-24 | 156 |
| Macko Todd D | Chief Financial Officer | Open market sale | 2026-03-27 | 43,400 |
| Grady Jason | Director | Open market sale | 2026-03-23 | 50,000 |
| Chan Heng Fai Ambrose | Director | Open market sale | 2025-04-04 | 180,000 |
| Heuszel Frank D | Chief Executive Officer | Open market purchase | 2024-12-05 | 500 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-24 | DSS, INC. | 10% owner | Open market sale | 156 | $7.06 |
| 2026-09-23 | DSS, INC. | 10% owner | Open market sale | 27 | $6.95 |
| 2026-09-22 | DSS, INC. | 10% owner | Open market sale | 723 | $0.55 |
| 2026-03-27 | Macko Todd D | Chief Financial Officer | Open market sale | 43,400 | $0.56 |
| 2026-03-25 | Macko Todd D | Chief Financial Officer | Open market sale | 1,600 | $0.60 |
| 2026-03-23 | Grady Jason | Director | Open market sale | 50,000 | $0.65 |
| 2025-05-27 | DSS, INC. | 10% owner | Open market sale | 45,400 | $0.54 |
| 2025-05-27 | DSS, INC. | 10% owner | Open market sale | 45,400 | $0.54 |
| 2025-05-22 | DSS, INC. | 10% owner | Open market sale | 115,600 | $0.55 |
| 2025-05-22 | DSS, INC. | 10% owner | Open market sale | 115,600 | $0.55 |
| 2025-04-04 | DSS, INC. | 10% owner | Open market sale | 890,800 | $0.95 |
| 2025-04-04 | Chan Heng Fai Ambrose | Director | Open market sale | 180,000 | $0.96 |
| 2025-04-03 | Chan Heng Fai Ambrose | Director | Open market sale | 351,555 | $0.49 |
| 2025-04-03 | Chan Heng Fai Ambrose | Director | Open market sale | 351,631 | $0.58 |
| 2025-04-03 | Chan Heng Fai Ambrose | Director | Open market sale | 273,286 | $0.78 |
| 2025-04-02 | Chan Heng Fai Ambrose | Director | Open market sale | 300,000 | $0.58 |
| 2025-04-02 | Chan Heng Fai Ambrose | Director | Open market sale | 200,000 | $0.67 |
| 2025-04-02 | Chan Heng Fai Ambrose | Director | Open market sale | 2,349 | $0.67 |
| 2025-04-02 | Chan Heng Fai Ambrose | Director | Open market sale | 382,427 | $0.58 |
| 2025-04-01 | Chan Heng Fai Ambrose | Director | Open market sale | 400,000 | $0.98 |
| 2025-04-01 | Chan Heng Fai Ambrose | Director | Open market sale | 650,000 | $1.45 |
| 2025-04-01 | Chan Heng Fai Ambrose | Director | Open market sale | 1,176,918 | $1.08 |
| 2025-03-31 | Chan Heng Fai Ambrose | Director | Open market sale | 300,000 | $1.03 |
| 2025-03-27 | DSS, INC. | 10% owner | Open market sale | 47,681 | $2.50 |
| 2025-03-26 | DSS, INC. | 10% owner | Open market sale | 48,281 | $3.13 |
| 2025-03-26 | DSS, INC. | 10% owner | Open market sale | 9,858 | $3.15 |
| 2025-03-21 | DSS, INC. | 10% owner | Open market sale | 166,600 | $3.30 |
| 2025-03-21 | DSS, INC. | 10% owner | Open market sale | 166,600 | $3.30 |
| 2025-03-21 | DSS, INC. | 10% owner | Open market sale | 166,600 | $3.30 |
| 2025-03-20 | DSS, INC. | 10% owner | Open market purchase | 200 | $1.55 |
| 2025-03-20 | DSS, INC. | 10% owner | Open market sale | 53,280 | $4.68 |
| 2024-12-05 | Heuszel Frank D | Chief Executive Officer | Open market purchase | 500 | $2.26 |
| 2024-12-02 | DSS, INC. | 10% owner | Open market sale | 20 | $2.90 |
| 2024-11-27 | Heuszel Frank D | Chief Executive Officer | Open market purchase | 500 | $2.61 |
| 2024-11-26 | Heuszel Frank D | Chief Executive Officer | Open market purchase | 550 | $2.62 |
| 2024-11-26 | Heuszel Frank D | Chief Executive Officer | Open market purchase | 500 | $2.59 |
| 2024-11-18 | DSS, INC. | 10% owner | Open market sale | 5,000 | $3.02 |
| 2024-11-13 | DSS, INC. | 10% owner | Open market sale | 200 | $2.80 |
| 2024-11-12 | DSS, INC. | 10% owner | Open market sale | 500 | $2.76 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 04:22 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-09 | 8-K | 2026-09-23 | View on SEC.gov → |
| 2026-09-24 | 4 | 2026-09-22 | View on SEC.gov → |
| 2026-09-17 | 8-K | 2026-09-16 | View on SEC.gov → |
| 2026-09-15 | 8-K | 2026-09-14 | View on SEC.gov → |
| 2026-08-07 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-05-12 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-03-30 | 4 | 2026-03-25 | View on SEC.gov → |
| 2026-03-25 | 4 | 2026-03-23 | View on SEC.gov → |
| 2026-03-11 | 10-K | 2025-12-31 | View on SEC.gov → |
| 2026-03-04 | 8-K | 2026-02-27 | View on SEC.gov → |
| 2026-01-06 | 4 | 2025-05-22 | View on SEC.gov → |
| 2025-11-07 | 10-Q | 2025-09-30 | View on SEC.gov → |
Recent news
Headlines about IBO (Impact BioMedical, Inc.). Links open the publisher — we don’t host full articles.
-
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 2026-10-15 -
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 2026-10-14 -
DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited
Yahoo Finance · 2026-09-16 -
Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)
Yahoo Finance · 2026-09-16 -
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)
Yahoo Finance · 2026-09-15 -
Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.)
Yahoo Finance · 2026-09-11 -
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Aug 2026
Seeking Alpha · 2026-09-02 -
Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans
Yahoo Finance · 2026-04-03
No headlines in this category right now — try “All”.